KA/EN
Register
Medicines reference
Search
Search
Active substance

Moxifloxacin

Favourites

Fluoroquinolone. Registered in Georgia: 1 human medicine. Forms: eye drops.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

No sourced safety entry is currently shown. This does not mean the substance is risk-free.

Latin name
Moxifloxacin
Georgian name
მოქსიფლოქსაცინი
Authorisation status
Human medicine, cascade use
No veterinary authorisation was found in any register checked. Veterinary use is off-label, under the prescribing cascade.
Registered in Georgia
1 of 1 forms
Products
Vigamox
Human medicines in Georgia
Avelox, Bivoxa, Demoxif, Dominal, Floxsafe, Heliomox, Mifalcin, Moflok, Moxicum, Moxin, Moxiqol, Moxiral, Pol-Moxi, Solumox, Torax, Vigamox
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Vigamox 5 mg/ml, Eye drops

eye drops, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Topical treatment of a diagnosed or strongly suspected susceptible bacterial ocular-surface infection, including selected conjunctivitis and keratitis; viral, fungal, sterile and intraocular disease are outside scope
7.2/10
Good
vetman assessment

Vigamox

5 mg/ml, eye drops, human medicine
Assessed clinical scopeDog · Topical treatment of a diagnosed or strongly suspected susceptible bacterial ocular-surface infection, including selected conjunctivitis and keratitis; viral, fungal, sterile and intraocular disease are outside scope · Into the eye
Care settingVeterinary-directed ocular treatment after examination and fluorescein assessment, with culture and urgent ophthalmology escalation when severity or response requires it
vetman score 7.2/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-043040 · Verified on 22 Oct 2026 Off-label use

A credible off-label topical option for selected susceptible canine bacterial conjunctivitis or keratitis after ocular examination. Exact-product transparency and direct tear/susceptibility data support a good score; resistance, limited controlled outcome evidence and diagnosis-specific regimens prevent broader claims.

Regulatory and scientific credibility8.0/10

The exact sterile 0.5% human ophthalmic product has a transparent FDA NDA/label and current Georgian and EU/EEA human registrations. Direct canine and feline ocular evidence supports a veterinary role, but it has no dog/cat authorisation and every assessed use is off-label.

Clinical efficacy6.5/10

Exact-product tear PK confirms ocular exposure and tolerability in healthy dogs, and contemporary canine keratitis series show useful moxifloxacin susceptibility. Clinical-outcome evidence is mostly observational or multi-treatment, resistance and MDR are substantial, and prior fluoroquinolone exposure can raise MIC; diagnosis and culture matter more than broad empiric confidence.

Safety and tolerability7.0/10

Topical exposure limits systemic burden and one exact-dose canine study found no ocular irritation, but diseased and repeatedly dosed eyes were not tested. Hypersensitivity, surface toxicity with very frequent use, contamination, resistant-organism or fungal overgrowth and delayed treatment of a deep/melting ulcer remain clinically important and require examination and early reassessment.

Clinical practicality7.5/10

A ready sterile preservative-free drop needs no reconstitution, is simple to place and avoids systemic dosing calculations. Repeated restraint, strict tip hygiene, variable disease-specific frequency, culture/rechecks and urgent escalation for severe ulcers remain real professional workflow burdens, but they are proportionate to ocular infection management.

Full-course cost-effectiveness-

Current comparable local full-course prices and wastage after opening were not verified.

Important safety and use flags

  • This score covers only selected diagnosed or strongly suspected susceptible bacterial ocular-surface infection. It does not cover FHV-1, fungal keratitis, eosinophilic or sterile keratitis, corneal sequestrum, uveitis, glaucoma, dry eye alone or intraocular infection.
  • Vigamox is a human medicine and all dog/cat use is off-label. Do not copy the human one-drop three-times-daily seven-day label as a universal veterinary regimen; site, depth, cytology, culture, severity and response determine the plan.
  • Perform a complete ocular examination, fluorescein staining and corneal-depth assessment before treatment. Deep, melting or rapidly progressive ulcer, anterior uveitis, severe pain, vision loss, suspected penetration or absent early improvement requires urgent ophthalmology review and may need surgery or systemic treatment.
  • Obtain cytology and culture with susceptibility testing before or promptly after starting therapy in deep, melting, recurrent, nosocomial, previously treated or poorly responding disease. Do not interpret historical aggregate susceptibility as proof that the current isolate is sensitive.
  • Fluoroquinolone exposure can select resistant organisms and increased MIC has been documented after topical exposure. Reserve broad-spectrum moxifloxacin for a coherent indication, narrow or change treatment when results permit, and do not extend prophylaxis or treatment without reassessment.
  • For ophthalmic use only. Never inject Vigamox into the eye or subconjunctivally; intraocular compounded moxifloxacin has separate formulation and toxicity concerns, and evidence for another vehicle or concentration cannot be transferred to this bottle.
  • Stop and reassess for hypersensitivity or marked worsening. Prolonged use can permit non-susceptible bacterial or fungal overgrowth; new infiltrate, increasing discharge, stromal loss, greater pain or deterioration despite treatment is not a reason simply to increase frequency.
  • Very frequent topical fluoroquinolone exposure can impair corneal epithelial healing and may promote melting. Intensive protocols may still be justified for a severe infected ulcer, but only with close veterinary or ophthalmology supervision; no universal maximum frequency is encoded here.
  • Avoid contamination: wash hands, do not touch the tip to the eye, lashes, skin or fingers, recap promptly and do not share one bottle between patients or contaminated eyes. Discard a bottle with damaged seal, altered solution or suspected contamination.
  • Record all concurrent ophthalmic products and separate drops by a practical interval so one does not wash out another; ointment is generally placed last. Review topical corticosteroids especially carefully: they are contraindicated with corneal ulceration and can worsen infection or melting.
Assessment sources
  1. Vigamox FDA label2017
  2. Vigamox GE register2026
  3. Vigamox EU register2026
  4. Exact Vigamox canine tear PK2026
  5. Canine keratitis susceptibility Brazil2024
  6. Canine keratitis susceptibility Korea2024
  7. Topical fluoroquinolone resistance2020
  8. Feline bacterial keratitis study2020
  9. Merck ophthalmic antimicrobials2025
  10. Ophthalmic antimicrobial stewardship2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Topical treatment of a diagnosed or strongly suspected susceptible bacterial ocular-surface infection, including selected conjunctivitis and keratitis; viral, fungal, sterile and intraocular disease are outside scope
7.0/10
Good
vetman assessment

Vigamox

5 mg/ml, eye drops, human medicine
Assessed clinical scopeCat · Topical treatment of a diagnosed or strongly suspected susceptible bacterial ocular-surface infection, including selected conjunctivitis and keratitis; viral, fungal, sterile and intraocular disease are outside scope · Into the eye
Care settingVeterinary-directed ocular treatment after examination and fluorescein assessment, with culture and urgent ophthalmology escalation when severity or response requires it
vetman score 7.0/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-043040 · Verified on 22 Oct 2026 Off-label use

A reasonable off-label topical option for selected susceptible feline bacterial ocular-surface infection, with useful in-vitro evidence but limited product-specific clinical outcomes. Confirm a bacterial component and do not let the drop substitute for antiviral, surgical or other disease-specific treatment.

Regulatory and scientific credibility8.0/10

The exact sterile 0.5% human ophthalmic product has a transparent FDA NDA/label and current Georgian and EU/EEA human registrations. Direct canine and feline ocular evidence supports a veterinary role, but it has no dog/cat authorisation and every assessed use is off-label.

Clinical efficacy6.0/10

A feline bacterial-keratitis series found high aggregate in-vitro moxifloxacin susceptibility, supporting it as a reasonable option when bacterial infection is likely. Product-specific feline cure trials are lacking, cohorts use multiple interventions, and common feline corneal disease may be viral or non-bacterial; susceptibility cannot be treated as guaranteed clinical cure.

Safety and tolerability7.0/10

Topical exposure limits systemic burden and one exact-dose canine study found no ocular irritation, but diseased and repeatedly dosed eyes were not tested. Hypersensitivity, surface toxicity with very frequent use, contamination, resistant-organism or fungal overgrowth and delayed treatment of a deep/melting ulcer remain clinically important and require examination and early reassessment.

Clinical practicality7.0/10

A ready sterile preservative-free drop needs no reconstitution or systemic dose calculation. Accurate placement may be harder in painful or poorly tolerant cats, while repeated restraint, strict tip hygiene, disease-specific frequency and short recheck intervals add burden; these are relevant clinical constraints rather than owner-convenience scoring alone.

Full-course cost-effectiveness-

Current comparable local full-course prices and wastage after opening were not verified.

Important safety and use flags

  • This score covers only selected diagnosed or strongly suspected susceptible bacterial ocular-surface infection. It does not cover FHV-1, fungal keratitis, eosinophilic or sterile keratitis, corneal sequestrum, uveitis, glaucoma, dry eye alone or intraocular infection.
  • Vigamox is a human medicine and all dog/cat use is off-label. Do not copy the human one-drop three-times-daily seven-day label as a universal veterinary regimen; site, depth, cytology, culture, severity and response determine the plan.
  • Perform a complete ocular examination, fluorescein staining and corneal-depth assessment before treatment. Deep, melting or rapidly progressive ulcer, anterior uveitis, severe pain, vision loss, suspected penetration or absent early improvement requires urgent ophthalmology review and may need surgery or systemic treatment.
  • Obtain cytology and culture with susceptibility testing before or promptly after starting therapy in deep, melting, recurrent, nosocomial, previously treated or poorly responding disease. Do not interpret historical aggregate susceptibility as proof that the current isolate is sensitive.
  • Fluoroquinolone exposure can select resistant organisms and increased MIC has been documented after topical exposure. Reserve broad-spectrum moxifloxacin for a coherent indication, narrow or change treatment when results permit, and do not extend prophylaxis or treatment without reassessment.
  • For ophthalmic use only. Never inject Vigamox into the eye or subconjunctivally; intraocular compounded moxifloxacin has separate formulation and toxicity concerns, and evidence for another vehicle or concentration cannot be transferred to this bottle.
  • Stop and reassess for hypersensitivity or marked worsening. Prolonged use can permit non-susceptible bacterial or fungal overgrowth; new infiltrate, increasing discharge, stromal loss, greater pain or deterioration despite treatment is not a reason simply to increase frequency.
  • Very frequent topical fluoroquinolone exposure can impair corneal epithelial healing and may promote melting. Intensive protocols may still be justified for a severe infected ulcer, but only with close veterinary or ophthalmology supervision; no universal maximum frequency is encoded here.
  • Avoid contamination: wash hands, do not touch the tip to the eye, lashes, skin or fingers, recap promptly and do not share one bottle between patients or contaminated eyes. Discard a bottle with damaged seal, altered solution or suspected contamination.
  • Record all concurrent ophthalmic products and separate drops by a practical interval so one does not wash out another; ointment is generally placed last. Review topical corticosteroids especially carefully: they are contraindicated with corneal ulceration and can worsen infection or melting.
Assessment sources
  1. Vigamox FDA label2017
  2. Vigamox GE register2026
  3. Vigamox EU register2026
  4. Exact Vigamox canine tear PK2026
  5. Canine keratitis susceptibility Brazil2024
  6. Canine keratitis susceptibility Korea2024
  7. Topical fluoroquinolone resistance2020
  8. Feline bacterial keratitis study2020
  9. Merck ophthalmic antimicrobials2025
  10. Ophthalmic antimicrobial stewardship2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Moxifloxacin5 mg/ml
Formulation Type
Eye drops
Administration route
Into the eye
Manufacturer
Novartis · Switzerland
Registration
Georgia Yes, human
In force until 21 Mar 2028
Human (Ministry of Health, RAMA)
№ რ-043040
Verified on: 22 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US Yes, human
№ NDA 021598
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified For ophthalmic use only. No single universal dog/cat frequency is published here: bacterial conjunctivitis, superficial keratitis, deep or melting ulcer and postoperative prophylaxis require different diagnostic and monitoring decisions. Perform a full ocular examination and fluorescein assessment; use cytology/culture for severe, deep, melting, recurrent or previously treated disease. Do not touch the dropper tip to the eye or surrounding tissue.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗